COPD Trial, Recruiting (NCT07406048)

COPD Trial, Recruiting NCT07406048 Sponsor: Chiesi Farmaceutica Ltda. Condition: COPD

Printed from Voxsanity (voxsanity.com.au) — NCT07406048 — Data sourced from ClinicalTrials.gov. Verify directly with the trial site before attending. Not medical advice.

Back to Copd

Who may be able to join

AI generated eligibility summary. Written by an AI model from the official source data and checked on a sample basis. It can contain mistakes, so confirm anything important against the original source. How we use AI

Who might be able to join this trial:

People who are 40 years of age or older at the time they started taking the medication BDP/FF/GB (a combination inhaler also known as Trimbow®)
People who have a documented diagnosis of severe or very severe COPD before starting BDP/FF/GB
People who had a COPD symptom score (called a CAT score) of 10 or higher around the time they started BDP/FF/GB, or within the 12 months before starting it
People who had at least one COPD flare-up (worsening of symptoms) in the 12 months before joining the study
People who started treatment with BDP/FF/GB either on the day they signed the consent form to join the study, or within the 3 months before signing it, in line with the approved prescribing guidelines for Trimbow®
People who are willing and able to give their written agreement to take part in the study

Who may not be able to join:

People who are already taking part in another clinical trial that involves a treatment or intervention, either during this study or in the 3 months before they started BDP/FF/GB

Important: Always verify eligibility with the trial site directly before applying.

Based on publicly available eligibility criteria from ClinicalTrials.gov. Verify directly with the trial site before acting. This is not medical advice.

This is a simplified plain English summary of the eligibility criteria. Full criteria are set by the trial investigators and may include additional requirements not shown here. Never self-exclude from a trial based on this summary. Contact the trial site directly to confirm your eligibility.

Last synced 28 July 2026

This study is not part of the standard drug-approval phase pathway (for example an observational, device, behavioural, or registry study), so a phase success rate does not apply.

Contact this trial

Principal Investigator: ROBERTO STIRBULOV, PhD, MD, Faculdade de Ciências Médicas da Santa Casa de São Paulo (FCMSCSP)

Phone: +551130952359 / +5511976281117

Contact details sourced from ClinicalTrials.gov. Verify directly with the trial site before attending.

GP referral letter

Print a one-page summary to share with your doctor.

Voxsanity

Clinical trials and treatments, explained plainly · voxsanity.com.au

Date:

To: My Doctor

Re: Clinical trial enquiry

I am writing to enquire about the following clinical trial which may be relevant to my care:

Trial: NCT07406048

Sponsor: Chiesi Farmaceutica Ltda.

Phase: Not Applicable

Status: Recruiting

Condition: COPD

Trial contact: +551130952359 / +5511976281117

More information: https://clinicaltrials.gov/study/NCT07406048

Eligibility summary (AI generated)

Written by an AI model from ClinicalTrials.gov eligibility criteria and checked on a sample basis. Please confirm against the original criteria.

Who might be able to join this trial:

People who are 40 years of age or older at the time they started taking the medication BDP/FF/GB (a combination inhaler also known as Trimbow®)
People who have a documented diagnosis of severe or very severe COPD before starting BDP/FF/GB
People who had a COPD symptom score (called a CAT score) of 10 or higher around the time they started BDP/FF/GB, or within the 12 months before starting it
People who had at least one COPD flare-up (worsening of symptoms) in the 12 months before joining the study
People who started treatment with BDP/FF/GB either on the day they signed the consent form to join the study, or within the 3 months before signing it, in line with the approved prescribing guidelines for Trimbow®
People who are willing and able to give their written agreement to take part in the study

Who may not be able to join:

People who are already taking part in another clinical trial that involves a treatment or intervention, either during this study or in the 3 months before they started BDP/FF/GB

Important: Always verify eligibility with the trial site directly before applying.

Access in Australia: A treatment being studied in a clinical trial is generally not yet listed on the PBS. Where a medicine is not approved or not available through a trial, the TGA Special Access Scheme may allow a doctor to access unapproved therapeutic goods for individual patients. See voxsanity.com.au/sas-navigator/ for a plain English explainer.

This information was sourced from ClinicalTrials.gov via Voxsanity (data last synced 28 July 2026). It is not medical advice. Please verify the trial's current status directly with the trial site before acting.

Trial details

Status

Recruiting

Phase

Not Applicable

Sponsor

Chiesi Farmaceutica Ltda.

Registry

ClinicalTrials.gov

Start date

1 April 2026

Est. completion

30 June 2027

Where this trial is recruiting

🇧🇷 Brazil

Primary endpoints

Assessment of the CAT (COPD assessment test) total score vs baseline at month 6

Can't join this trial?

Expanded access pathways

If this trial is not available to you, other access pathways may exist. In Australia, the TGA Special Access Scheme allows access to unapproved therapeutic goods for individual patients.

TGA Special Access Scheme information

Find other recruiting trials on ClinicalTrials.gov

Data last synced from ClinicalTrials.gov: 28 July 2026. Trial status can change. Always verify current status directly with the trial site before making any decision.

Trial recruitment status can change without notice between our nightly data updates. Always contact the trial site directly to confirm current recruitment status before making any decisions or travel arrangements.

View original record on ClinicalTrials.gov